Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Tax Rate (2019 - 2023)

Historic Tax Rate for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q1 2023 value amounting to 29.05%.

  • Lineage Cell Therapeutics' Tax Rate changed N/A to 29.05% in Q1 2023 from the same period last year, while for Dec 2023 it was 7.74%, marking a year-over-year decrease of 483500.0%. This contributed to the annual value of 7.74% for FY2023, which is 98400.0% up from last year.
  • Lineage Cell Therapeutics' Tax Rate amounted to 29.05% in Q1 2023.
  • In the past 5 years, Lineage Cell Therapeutics' Tax Rate registered a high of 262.3% during Q4 2019, and its lowest value of 9.7% during Q3 2022.
  • In the last 4 years, Lineage Cell Therapeutics' Tax Rate had a median value of 11.44% in 2021 and averaged 42.29%.
  • Data for Lineage Cell Therapeutics' Tax Rate shows a peak YoY increase of -211400bps (in 2022) and a maximum YoY decrease of -211400bps (in 2022) over the last 5 years.
  • Lineage Cell Therapeutics' Tax Rate (Quarter) stood at 262.3% in 2019, then tumbled by -96bps to 11.44% in 2021, then tumbled by -185bps to 9.7% in 2022, then soared by 399bps to 29.05% in 2023.
  • Its last three reported values are 29.05% in Q1 2023, 9.7% for Q3 2022, and 11.44% during Q3 2021.